| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1373886 | Bioorganic & Medicinal Chemistry Letters | 2009 | 4 Pages |
A novel series of antagonists of the human A2A receptor have been identified and have been shown to display good potency and high degrees of selectivity over other receptor sub-types. Displaying in vivo potency in commonly used disease models and high oral bio-availability, this class of compounds may serve as clinically useful treatments for the relief of the symptoms associated with Parkinson’s disease.
Graphical abstractA novel series of antagonists of the human A2A receptor demonstrate potency and selectivity over other receptor sub-types. Displaying in vivo potency in commonly used disease models and high oral bio-availability, this class of compounds may serve as clinically useful treatments for the relief of the symptoms associated with Parkinson’s disease.Figure optionsDownload full-size imageDownload as PowerPoint slide
